chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Swollen lymph nodes in arm pit; Lymph nodes in arm pit painful; This is a spontaneous report from a contactable consumer, the patient. A 17-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0151) via an unspecified route of administration in the left arm on 05Apr2021 at 09:45 (at the age of 17-year-old) as dose 2, single for COVID-19 immunization. Medical history included asthma. The patient had known allergies to contrast media and penicillin. Concomitant medication was not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration in the left arm on 16Mar2021 at 09:15 (at the age of 17-year-old) as dose 1, single for COVID-19 immunization. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021, the patient experienced swollen lymph nodes in arm pit, painful and tender armpit. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of reported events. The clinical outcome of the events was not recovered.   No follow-up attempts are needed. No further information is expected.  Amendment: This follow-up report is being submitted to amend previously reported information: Narrative amended.
Tdap administered 04/14/12 local increased redness, mild edema, increased local skin temp & c/o pain & itching at site gradually developed; Dx: cellulitis Rx: KEFLEX.
Pt came in for first dose Covid vaccination. Due to allergy history pt was instructed to wait in observation area for 30 mins. Roughly 35 mins into observation time, pt reported feeling itchy and having a scratchy throat. Pt notified writer she took her own dose of 25mg of oral benadryl. Continued to monitor pt - pt reported no improvement but no worsening of symptoms. 30 min after dose of benadryl pt stated she did not want additional medication at this time. Pt stable. Pt instructed to follow up with PCP/allergist and knows to not come back to clinic if she thinks she needs additional medical attention.
developed severe abdominal pain on 2/13. denied fever/chills, vomiting or diarrhea
Swelling on 04.20.16, fever of 102 degrees F on 04.21.16.  Diagnosed with phlebitis/thrombophlebitis 04.22.16 -given Zpak.
pt had severe headache, diarhea, fever and sore left arm.  These symptoms lasted about 3 days except the sore arm.  Pts left arm pain never subsided and she had limited mobility.  She rcvd the 2nd dose on 4/26/21 @ 10:45 in the left arm (lot # EW0161).  Pt developed the same exact symptoms as she had with the 1st dose, the headache, diarhea, fever, and sore left arm.  On 5/21/21 pt still has alot of pain with headache and sore left arm with very limited mobility.  Pt will contact her PCP regarding her symptoms.
PAIN IN EXTREMITY; DIZZINESS; ERYTHEMA; OEDEMA PERIPHERAL; SKIN WARM; NAUSEA. Information has been received from a registered nurse concerning a 23 year old Caucasian female patient who on 13-May-2003 at 10:00 AM was vaccinated with a first dose of hepatitis B virus vaccine rHBsAg (yeast) (lot # 643165/0217M), in the left deltoid. On that same day, the patient received a TB test in the opposite arm. On 19-may-2003 at 4:00 PM the patient complained of "pain in arm while trying to turn on light." The patient developed "a band of redness encircling her arm and her arm hurts so much that she cannot raise the arm." There was also swelling noted below deltoid area left inner arm. The patient also reportedly had "red warm area 2 in. wide by 4 in. long." The patient also complained of nausea and was lightheaded. The patient sought unspecified medical attention. It was reported that the "symptoms were gone a week later." The patient recovered on 27-may-2003. It was also noted that the patient received a second dose of hepatitis b virus vaccine rHBsAg (yeast) on 20-Jun-2003 with "no adverse effects." It was also reported that another patient had similar symptoms (WAES0305USA02041). Additional information has been requested.
we had a few patients that were vaccinated with a vaccinethat was 50 days in the refrigerator; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (we had a few patients that were vaccinated with a vaccinethat was 50 days in the refrigerator) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (we had a few patients that were vaccinated with a vaccinethat was 50 days in the refrigerator). At the time of the report, EXPIRED PRODUCT ADMINISTERED (we had a few patients that were vaccinated with a vaccinethat was 50 days in the refrigerator) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant medications were reported. No Treatment information was provided.
no adverse event; multiple patients were vaccinated with an improperly stored vaccine; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant therapies were not reported.  On 22-MAY-2019, the patient was vaccinated with an improperly stored dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ), 2 ml, orally (LOT# R034700, expiry date 16-JUN-2020) for prophylaxis. The vaccine was exposed to a temperature of 34.2 Fahrenheit degrees (F) for 4 hours and 54 minutes. Digital data logger was involved. There were no previous temperature excursions. No adverse effects were reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1907USA000862: US-009507513-1907USA000882: US-009507513-1907USA000883: US-009507513-1907USA000884: US-009507513-1907USA000885: US-009507513-1907USA000886: US-009507513-1907USA000887: US-009507513-1907USA000888: US-009507513-1907USA000889: US-009507513-1907USA000890: US-009507513-1907USA000891: US-009507513-1907USA000892: US-009507513-1907USA000893: US-009507513-1907USA000894: US-009507513-1907USA000895: US-009507513-1907USA000896: US-009507513-1907USA000897: US-009507513-1907USA000898: US-009507513-1907USA000899: US-009507513-1907USA000900: US-009507513-1907USA000901: US-009507513-1907USA000902: US-009507513-1907USA000903: US-009507513-1907USA000904: US-009507513-1907USA000905: US-009507513-1907USA000906: US-009507513-1907USA000907: US-009507513-1907USA000908: US-009507513-1907USA000909: US-009507513-1907USA000910: US-009507513-1907USA000911: US-009507513-1907USA000912: US-009507513-1907USA000914: US-009507513-1907USA000915: US-009507513-1907USA000916: US-009507513-1907USA000917: US-009507513-1907USA000918: US-009507513-1907USA000919: US-009507513-1907USA000920: US-009507513-1907USA000921: US-009507513-1907USA000922: US-009507513-1907USA000923: US-009507513-1907USA000924: US-009507513-1907USA000925: US-009507513-1907USA000926: US-009507513-1907USA000927: US-009507513-1907USA000928: US-009507513-1907USA000929: US-009507513-1907USA000930: US-009507513-1907USA000931: US-009507513-1907USA000932: US-009507513-1907USA000933: US-009507513-1907USA000934: US-009507513-1907USA000935: US-009507513-1907USA000936: US-009507513-1907USA000937: US-009507513-1907USA000938: US-009507513-1906USA011674:
devel red, swollen deltoid w/in 12hr; painful w/radiation to shoulder; pain cont p/resolution of redness & edema & advanced from shoulder to neck; still has shoulder & neck pain, 8 wk later
accidentally administered the vaccine to a 13-year-old; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (accidentally administered the vaccine to a 13-year-old) in a 13-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Aug-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (accidentally administered the vaccine to a 13-year-old) (seriousness criterion medically significant). On 12-Aug-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (accidentally administered the vaccine to a 13-year-old) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not provided by the reporter. Treatment medications were not provided by the reporter.  This is a case of inappropriate age (13yrs) at vaccine administration with no adverse events. Additional information is requested.   Most recent FOLLOW-UP information incorporated above includes: On 16-Aug-2021: Follow up received and contains no new information; Sender's Comments: This is a case of inappropriate age (13yrs) at vaccine administration with no adverse events. Additional information is requested. MOD21-129585:cross linked
experienced all the common side effects; This case was reported by a consumer via call center representative and described the occurrence of adverse drug reaction in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, less than 6 months after receiving Shingrix, the patient experienced adverse drug reaction. On an unknown date, the outcome of the adverse drug reaction was unknown.   It was unknown if the reporter considered the adverse drug reaction to be related to Shingrix.  Additional details were received as follows: The age at vaccination was not reported. The patient experienced all the common side effects after vaccination. This case has been linked to US2019AMR238651, reported by the same reporter.
Patient with smallpox vaccine on 1 Oct 08.  That evening w/ flesh closed papules on forehead which progressed to back of ears by the morning.  No pustules.  Rash did not improve or worsen.  Seen in clinic on 6 Oct 08.  No other symptoms.  Likely not vaccine related due to timing and recent change of laundry detergent.  No history of atopic dz.
A few hours after the administration of the vaccine mom noted a rash at the site of the injection.  It has spread over the last week on the entire anterior surface of the left thigh.
pt recvd vax & exp n, d & was lethargic; sxs recurred intermittent; 19sep94 sxs returned scan indicated pt devel mult sclerosis;
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Apr-2021 at 11:26 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 27-Apr-2021 at 11:26 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). In 2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 34.02.  No concomitant medications were reported.  Batch number 007C21A administered on 27-Apr-2021 had  temperature of 35 at 09:00 AM, 34 at 10.00AM and 35 at 01.00 PM. This vial was moved to fridge on 19-Apr-2021 and beyond use date for the vial was reported as 19-May-2021. Product moved to clinic on 27-Apr-2021.  Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a traceable temperature monitor at every hour.  No treatment medications were reported
01/26/1021 -shortness of breath, 01/27/2021 shortness of breath & low grade temp, 01/27/2021 wheezing & 100.0 temp; taken to ER, admitted to hospital ; released from hospitol on 01/30/2021, with oral antibitoics & predinsone.
got 2 vaccines, sore arm; This case was reported by a consumer via  interactive digital media and described the occurrence of pain in arm in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was unknown.   It was unknown if the reporter considered the pain in arm to be related to Shingles vaccine.  Additional details were reported as follows: The case was reported by the patient. The age at vaccination was not reported. The patient got the 1st vaccines of shingles and experienced reaction was a sore arm. The follow-up would not possible as no contact details were available. For tolerance of 2nd dose refer case US2021AMR186349.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR186349:2nd dose
This spontaneous report as received from a pharmacist refers to a 71 year old male patient. On 16-SEP-2014, the patient was vaccinated with PNEUMOVAX 23 injection with lot number J006242 and expiry date 03-AUG-2014 (0.5 ml, subcutaneously) as vaccine. No concomitant medication was reported. It was noticed that, on 16-SEP-2014, the patient was administered with expired PNEUMOVAX 23. Potency supported and no adverse effects were experienced by the patient. The outcome of the events were unknown. The patient did not sought medical attention. A product quality complaint (PQC) was not involved. Additional information has been requested.
This spontaneous report was received from a pharmacist refers to a 66 year old male patient. The patient has concurrent condition of hypercholesterolaemia and hypertension. On 13-JUL-2015, the patient was vaccinated with ZOSTAVAX lot # L012475, expiry date 10-JUL-2016, subcutaneous. Concomitant therapies included pravastatin (manufacturer unknown) and unspecified hypertension medication. On 13-JUL-2015, the patient developed a red, warm welt at the injection site a few hours after administration of ZOSTAVAX. No Lab diagnostics were performed. On 16-JUL-2015, the outcome of warm welt at the injection site was reported as recovered/resolved. The patient sought medical attention (came to pharmacy). Additional information has been requested.
Redness after shot-swelling,very sore muscles & now I go to therapy (shoulder frozen) (6 wks- later) Cortizone Injections
This spontaneous report as received from a registered nurse refers to a 15 month old patient of an unknown gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided. On 17-OCT-2017, the patient was vaccinated with an adult dose of VAQTA, 50 U/1 ml (route of administration, lot# and expiration date were not reported). No adverse effects were reported.
pt recv vax 1JUN95 & 19JAN97 pt exp a chickenpox rash on back & stomach w/approx 11 vesicular lesions;
PT given TD for wound on leg obtained while working in construction. Developed mild wheals near vaccine site. 30 minutes after vaccination, not relieved by Benadryl. Came back to clinic after 1 hour with diffuse wheal trunk, arms and swollen lips and tongue. No dyspnea. Given Benadryl, Zyrtec Epinephrine. Sent to ER. 12/12/06 Received medical records from hospital which reveal patient seen in ER with rash & facial/lip swelling s/p receipt of epi & oral Benadryl at urgent care center.  D/C to home same day on tapering prednisone & benadryl. Final Dx: Allergic reaction to dT shot.
Patient came to IMMs complaining of redness rash, itching and soreness under arm of ACAM2000 vaccination site.
Hospitalized 9/15/2021; COVID-19 positive 9/14/2021; fully vaccinated  Patient is a 73 year old male with a past medical history of DM 2, Frontotemporal dementia, CKD 4, atrial flutter on chronic Eliquis, OSA, and obesity that presented due to Epistaxis.  He was sent to the ED from his longterm care facility with epistaxis.  He is on a blood thinner.  He was sick for approximately 3-4 days prior to admit with cough, fever and diarrhea.  He tested positive for COVID on 9/14.  He had decreased oral intake as well.  He was transiently hypoxic in the ED.  He was placed on 1L.  Chest xray showed no abnormality.  He quickly weaned off of oxygen.  This was not felt to be due to COVID.  Likely there were other explanations.  He received Monoclonal Antibodies.  His kidney function improved with IVF.  He resumed his Lasix at d/c.  He was discharged back to longterm care on 9/21/21.
At site redness appeared day 4 = approximately 3 cm diameter smooth, no opening, slightly firm 'to touch'.
Fever, Chills,  Headache, Sinus Congestion, Sore Arm, Body Aches, Nausea  All started Friday morning (1/15/21) after receiving the vaccine Thursday afternoon (1/14/21). Patient stated that the symptoms improved Saturday afternoon (1/16/21) and had completely stopped by Monday morning  (1/18/21) when she woke up.  Stated symptoms were not bad enough to seek medication attention.
Initial report was received from a health care professional on 20 September. A 64 year-old female patient with an allergy to erythromycin and a history of anemia, skin cancer and osteoarthritis had received on 12 September 2011 an intramuscular right arm injection of ADACEL, lot number C3927AA and an intramuscular right arm injection of PNEUMOVAX (Merck lot number not reported). The next day on 13 September 2011, the patient experienced redness, swelling, induration, hot to touch upper arm area of the right arm. The patient was diagnosed with cellulitis and was hospitalized for two days (dates not reported). Treatments were not reported. Concomitant medication included CLIMERA, Multivitamin and probiotic formula cap. Illnesses at the time of vaccination, adverse events following prior vaccinations and any other vaccines within four weeks of suspect vaccines were reported as none. No further information was available at the time of the report. The patient's outcome was not reported. Documents held by sender: none.
Got very dizzy and had to sit down. I then began to start shaking and felt like I needed to use the bathroom. During the walk to the bathroom I started to sweat a great amount and fainted for about 10 seconds. After waking up I was still dizzy and sweating. I then had diarrhea. After this, I started to return to normal.
- Onset of rash on left upper arm the next day after injection.  Report mild pain when laying on the affect arm side (has resolved).  Report that rash appeared bigger in size today (6/27).  Main symptom is itchiness and warmth from rash site.
The resident was scheduled to receive a third dose at a clinic on 9/15/21. Patient went to pharmacy just prior and got the dose and it was not reported - causing the patient to get a duplication of the 3rd dose. Pt also had 2 covid cards.
Area hot, swollen and spreading down to elbow; cold sweats; temperature 97F; dizzy; BP 145/92; nausea; burning eyes and myalgias.
Sore throat; This is a spontaneous report from a non-contactable consumer, the patient. A 53-years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 30Mar2021(at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient was allergic to penicillin, sulfonamide, iodine and contrast media. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, it was unknown whether the patient had been tested for COVID-19 . The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021, the patient experienced the event sore throat. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event sore throat was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Discussed vaccine ADE after first dose with patient. Pt reports having existing lung disease for which she uses oxygen and CPAP overnight. She reports feeling fatigued and increased SOB on exertion and increased O2 requirement for 2d after  receiving vaccine. She also reports intermittent sweating and feeling hot on her head and scalp but without chills or bodyaches for 3 weeks now. When she checked her temperature at home, she reports temps of 98 or 99. Based on discussion, her reaction is not  likely to be an allergic reaction and more likely an immune response to vaccine. Patient agrees to proceed with 2nd dose and will continue to monitor symptoms.